Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab combined with fruquintinib or regorafenib for previously treated BRAF V600E-mutant MSS advanced colorectal cancer
ChiCTR2100043066Phase 4Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, fruquintinib and regorafenib in colorectal cancer (CRC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Started Feb 2021; status: recruiting.
02
Drugs
camrelizumabfruquintinibregorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100043066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043066.